Research

Hormonal

Aberrant protein posttranslational modifications (PTMs) are central drivers of metabolic diseases including diabetes, obesity, and atherosclerosis, and targeting these modifications offers a viable therapeutic strategy.

Metabolic diseases are driven by complex molecular switches (PTMs) that regulate how your body processes energy. While lifestyle changes are the first line of defense, pharmaceutical interventions targeting these specific molecular pathways (like kinase inhibitors) are increasingly available and effective for managing conditions like diabetes and fatty liver disease when lifestyle changes are insufficient.

ModerateSupportsMEDIUM confidence
Aberrant PTMs are implicated in diverse human diseases, including metabolic disorders and CVDs. ... Drugs targeting PTMs have thus provided potential therapeutic strategies in the study of diverse diseases, including metabolic disorders.
Xiumei Wu et al. · Signal Transduction and Targeted Therapy · 2023

Why this rating

This is a review article summarizing preclinical and clinical evidence; it is not a primary clinical trial itself.

Source

Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies

Xiumei Wu et al. · Signal Transduction and Targeted Therapy · 2023

DOI 10.1038/s41392-023-01439-y

narrative_reviewCited 228×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →